Yangzijiang Pharmaceuticals' "Entikave oral solution" was approved for the first time

On November 19, the latest approval of NMPA showed that Yangzijiang Pharmaceuticals' Class 3 generic drug "Entekave Oral Solution" was approved, successfully obtaining the first domestic imitation of the variety.
ETV is a nucleoside antiviral drug used in the treatment of chronic hepatitis B.
the drug was first developed by Shishi Shiguibao, first approved in China in 2005, has become a first-line treatment of hepatitis B drugs.
public data show that in 2019, the domestic public medical institutions terminal Endikave sales of more than 7 billion yuan, but mainly tablets and capsules, the market share with a positive day, 48.93 percent, the original research ShiGuibao accounted for 26.44 percent.
Insight database, there are currently six dosage forms in the country, including tablets, dispersion tablets, capsules, oral solutions, particles and Malay acid entecave tablets.
the first three of them have been included in the 4 plus 7 episodes, and the 33 have not yet been approved for domestic generic drugs before this Yangzijiang approval.
from: Insight database () for Entekave oral solution, the original research hundred-time Meishi Guibao pharmaceutical is still in clinical applications, there are few domestic enterprises to apply.
addition to the yangzijiang pharmaceutical industry approved this time, Only Anhui New Century Pharmaceuticals submitted a new registration classification listing application on September 17 this year.
addition, Stadt Pharmaceuticals was approved for clinical practice in December 2019.
from: Insight Database ()